Vaccine Responses in Cancer

NCT06605625 | Active Not Recruiting FDA Drug

• 2 other identifiers: 852151UPCC27922
• Study Type: observational
• Target: 250
• Locations: 1 country
• Sites: 1

Brief Summary

The investigators are conducting a prospective unblinded study of individuals diagnosed with cancer who will receive one or more of the following: influenza, SARS-CoV2 and shingles.

Conditions

Viral Vaccines

Keywords

influenza

Outcome Measures

Primary Outcomes (1)

• Neutralizing antibody response

  The neutralizing antibody titer will be assessed by measurement of the hemagglutinin-inhibition titer before and after influenza vaccination in order to determine the seroconversion rate. The late blood draw may occur between days 45-90 following vaccination.

  45-90 days

Study Arms (1)

Patients with Cancer

Patients with cancer who are clinically indicated to receive influenza, recombinant shingles and/or SARS-CoV2 vaccine

Biological: Influenza vaccination; Biological: SARS-CoV-2 vaccine; Biological: Zoster Vaccine Recombinant

Interventions

Influenza vaccination BIOLOGICAL

one annual dose of inactivated influenza vaccine

Patients with Cancer

SARS-CoV-2 vaccine BIOLOGICAL

dose of SARS CoV2 vaccine

Patients with Cancer

Zoster Vaccine Recombinant BIOLOGICAL

first and/or second vaccination for shingles (Herpes zoster)

Patients with Cancer

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with cancer who are clinically indicated to receive influenza, recombinant shingles (Shingrix) and/or SARS-CoV-2 vaccine

You may qualify if:

• adults over age 18 who are able to provide consent, who have a diagnosis of cancer, and are willing to receive the influenza, recombinant shingles, and/or SARS-CoV-2 vaccines.

You may not qualify if:

• allergic to influenza, shingles, and/or SARS-CoV-2 vaccination; have HIV infection; have a history of solid organ or bone marrow transplant.

Sponsors & Collaborators

• Abramson Cancer Center at Penn Medicine: lead

Study Sites (1)

University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

Location

Biospecimen

Retention: SAMPLES WITH DNA

blood

MeSH Terms

Conditions

Influenza, Human

Interventions

Influenza Vaccines; COVID-19 Vaccines

Condition Hierarchy (Ancestors)

Respiratory Tract Infections; Infections; Orthomyxoviridae Infections; RNA Virus Infections; Virus Diseases; Respiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Viral Vaccines; Vaccines; Biological Products; Complex Mixtures

Study Officials

• E. John Wherry, PhD

  Univeristy of Pennsylvania

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 18, 2024
• First Posted: September 20, 2024
• Study Start: November 4, 2022
• Primary Completion (Estimated): October 1, 2027
• Study Completion (Estimated): October 1, 2028
• Last Updated: October 28, 2025

Record last verified: 2025-10

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)